Vericel (VCEL) closed at $42.53 on Oct 23, 2026, down 1.0% on the day. The stock is up 8.2% over the past month, down 6.2% over three months, up 18.1% year to date and up 16.7% over the past year. It trades 13.8% below its 52-week high of $49.32 and 46.9% above its 52-week low of $28.95. The close sits above its 50-day moving average ($40.72) and above its 200-day moving average ($38.55).
NextPick tracks VCEL in its Cell / Gene Therapy basket alongside CRSP, BEAM, NTLA, PRME and EDIT. As of Oct 23, 2026, the basket's money-flow score is -10 (neutral), and the basket is up 4.7% over five sessions. Over the past month VCEL ranks 2nd of 7 basket members by price change.
Form 4 filings over the last 90 days show no open-market purchases and 5 open-market sales by insiders.
Yes — the Oct 23, 2026 close of $42.53 is 10.3% above the 200-day average of $38.55.
VCEL closed 13.8% below its 52-week high of $49.32.
NextPick groups VCEL with CRSP, BEAM, NTLA, PRME and EDIT in its Cell / Gene Therapy basket.
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.
